Exact Sciences Corporation
Exact Sciences Corporation (EXAS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
exas · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Exact Sciences Corporation (EXAS) measures how much investors pay for each dollar of the company's trailing earnings. EXAS's current PE ratio of N/A is calculated by dividing its stock price of $104.91 by its TTM earnings per share of -$1.10.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Exact Sciences CorporationYou EXAS | $20.0B | N/A | — | -$1.10 |
 BridgeBio Pharma, Inc. BBIO | $13.2B | N/A | — | -$3.70 |
 Doximity, Inc. DOCS | $3.9B | 22.23x | -38.1% | $1.05 |
 Guardant Health, Inc. GH | $16.7B | N/A | — | -$3.32 |
 ICON Public Limited Company ICLR | $11.4B | 62.31x | +73.6% | $2.92 |
 Qiagen N.V. QGEN | $7.6B | 23.17x | -35.5% | $2.04 |
 Roivant Sciences Ltd. ROIV | $20.6B | N/A | — | -$0.43 |
Industry Average 3 peers with valid PE | — | 35.90x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.10 | — | |
2024-12-31 FY2024 | — | $-5.59 | — | |
2023-12-31 FY2023 | — | $-1.13 | — | |
2022-12-31 FY2022 | — | $-3.54 | — | |
2021-12-31 FY2021 | — | $-3.48 | — | |
2020-12-31 FY2020 | — | $-5.45 | — | |
2019-12-31 FY2019 | — | $-1.62 | — | |
2018-12-31 FY2018 | — | $-1.43 | — | |
2017-12-31 FY2017 | — | $-0.99 | — | |
2016-12-31 FY2016 | — | $-1.63 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Exact Sciences Corporation (EXAS) measures how much investors pay for each dollar of the company's trailing earnings. EXAS's current PE ratio of N/A is calculated by dividing its stock price of $104.91 by its TTM earnings per share of -$1.10.
Frequently asked questions
EXAS pe ratio · 6 questionsEXAS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $104.91 and TTM EPS of -$1.10. Data sourced from Financial Modeling Prep via EXAS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Exact Sciences Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08